February 22, 2018

How MPN Blood Cancers outsmart the Immune System

AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE Researchers have discovered how some of the blood cancers known as myeloproliferative neoplasms (MPNs) evade the immune system.  Their […]
February 1, 2018
clinical trial in myelofibrosis

Imago BioSciences gets FDA Approval of IND Application for Treatment of Myelofibrosis, IMG-7289 in Clinical Trials

Imago BioSciences, a clinical-stage pharmaceutical company developing novel therapies for hematological and inflammatory diseases, announced that the U.S. Food and Drug Administration (FDA) has accepted their […]
January 8, 2018
Celgene MPN drug Fedratinib

Celgene Acquires Impact Biomedicines, Adding Myeloproliferative Neoplasm Drug Fedratinib to Its Pipeline

Celgene Corporation (NASDAQ:CELG) and Impact Biomedicines today announced the signing of a definitive agreement in which Celgene will acquire Impact Biomedicines, which is developing fedratinib for […]
December 27, 2017
Dr Mascarenhas presenting at ASH 2017 on Nutlin

ASH 2017 Nutlin Antagonist Shows Activity in Polycythemia Vera

The investigational Nutlin family antagonist idasanutlin demonstrated significant activity and was well tolerated after multiple cycles of exposure in patients with refractory polycythemia vera (PV). Data […]
December 1, 2017

What is an MPN Specialist?

One Simple Criteria If your doc has never been to the ASH (American Society of Hematology) conference, the largest hematology convention in the world and never […]
June 29, 2017
Pegasys Jakafi combo for MPNs

Minimal Residual Disease or Cure in MPNs? Rationales and perspectives on Combo Therapy with Interferon-alpha2 and Ruxolitinib

This abstract is provided by Mads Emil Bjorn & Hans Carl Hasselbalch – Department of Hematology, Region Zealand, Roskilde, Denmark Abstract Introduction: The therapeutic landscape of […]